Alkem Laboratories Ltd
ALKEM (NSE)

4,000.00

47,826.00
Proj. ROE (%)
20.39
Proj. P/E (x)
29.19
Proj EV / EBITDA (x)
22.11
Proj. P/BV (x)
5.63
Proj. Revenue ( Cr.)
10,297.50

Stock View

BUY
Share on
The average score for Alkem Laboratories Ltd stands at 7 against 8, three months back.

Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
3,680.59
100 DMA ()
3,397.62
200 DMA ()
3,126.36
52 Weeks Range
2,540.05
4,070.00
Street View :-
Bearish
Open ZERO Brokerage Demat Account